Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15544191 | 0.98 | HTR3A (0.67) | HTR3ASLC6A2SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL28289382 | 0.85 | HTR3A (0.57) | HTR3ASLC6A2SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL26690667 | 0.82 | HTR3A (1.00) | HTR3ASLC6A2SLC6A3 | |
| SCHEMBL447190 | 0.82 | HTR3A (1.00) | HTR3ASLC6A2SLC6A3 | |
| SCHEMBL6902944 | 0.82 | HTR3A (1.00) | HTR3ASLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL23455778 | 0.82 | HTR3A (0.50) | HTR3ASLC6A2SLC6A3 | |
| SCHEMBL16446546 | 0.81 | HTR3A (0.81) | HTR3ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL308190 | 0.81 | HTR3A (0.81) | HTR3ASLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL29908691 | 0.81 | HTR3A (0.96) | HTR3ASLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL4573036 | 0.81 | HTR3A (0.96) | HTR3ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704125-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119528923-A | Tri-fused ring compound and preparation method and application thereof | 韦恩生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-11939320-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2024-03-26 | — | — | US | disclosed |
| CN-117580824-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4237413-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230192712-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2023-06-22 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-9428502-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015112441-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-6831078-B1 | 3-aryl substituted having halo or alkylhalo groups; anxiety, epilepsy; presurgery muscle relaxant | VERNALIS RESEARCH LIMITED (GB) | 2004-12-14 | — | — | US | disclosed |
| EP-1049670-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RES LTD (GB) | 2002-07-17 | — | — | EP | disclosed |
| EP-1196165-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007022-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| EP-1049670-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037613-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | HTR3A 2060/4885SLC6A2 3340/4885SLC6A3 4260/4885 |
| US-11939320-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | HTR3A 2866/4885SLC6A2 2340/4885SLC6A3 3310/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTR3A 1989/4885SLC6A2 1180/4885SLC6A3 2255/4885 |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | HTR3A 3035/4885SLC6A2 3253/4885SLC6A3 3929/4885 |
| US-20230192712-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTR3A 2866/4885SLC6A2 2340/4885SLC6A3 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.